Table 3. The sRANKL/OPG ratio and breast cancer risk by hormone-receptor subtype: EPIC nested case-control study.
| Quintiles |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | |||||
| Cut points* | < 0.003 | 0.003-0.008 | 0.008-0.014 | 0.014-0.0226 | ≥ 0.0226 | ptrend† | log2 | phet‡ | phet§ |
| Whole population | |||||||||
| ER+/PR+ | |||||||||
| Cases/Controls | 146/177 | 175/181 | 186/178 | 184/180 | 224/199 | 915/915 | |||
| RR (95% CI) | ref. | 1.17 (0.84-1.63) | 1.26 (0.90-1.76) | 1.21 (0.86-1.69) | 1.42 (1.01-1.98) | 0.21 | 1.04 (0.98-1.10) | 0.02 | |
| ER+ | |||||||||
| Cases/Controls | 296/328 | 332/333 | 311/318 | 301/306 | 350/305 | 1590/1590 | |||
| RR (95% CI) | ref. | 1.13 (0.90-1.43) | 1.12 (0.88-1.42) | 1.10 (0.86-1.40) | 1.33 (1.03-1.71) | 0.12 | 1.03 (0.99-1.08) | 0.05 | |
| ER-/PR- | |||||||||
| Cases/Controls | 45/41 | 46/42 | 53/47 | 60/60 | 46/60 | 250/250 | |||
| RR (95% CI) | ref. | 1.10 (0.56-2.15) | 1.04 (0.55-1.98) | 0.86 (0.44-1.66) | 0.60 (0.31-1.14) | 0.03 | 0.88 (0.78-0.99) | ||
| ER- | |||||||||
| Cases/Controls | 70/66 | 70/60 | 80/76 | 79/87 | 78/88 | 377/377 | |||
| RR (95% CI) | ref. | 1.24 (0.73-2.09) | 0.93 (0.56-1.55) | 0.77 (0.46-1.31) | 0.74 (0.44-1.25) | 0.10 | 0.92 (0.84-1.01) | ||
| Age at diagnosis <50 years | |||||||||
| ER+/PR+ | |||||||||
| Cases/Controls | 7/10 | 20/20 | 17/25 | 28/18 | 48/47 | 120/120 | |||
| RR (95% CI) | ref. | 0.65 (0.16-2.74) | 0.36 (0.07-1.74) | 1.14 (0.29-4.51) | 0.94 (0.25-3.58) | 0.48 | 1.08 (0.87-1.35) | ||
| ER+ | |||||||||
| Cases/Controls | 11/12 | 23/24 | 21/29 | 31/24 | 56/53 | 142/142 | |||
| RR (95% CI) | ref. | 0.58 (0.16-2.05) | 0.36 (0.10-1.36) | 0.79 (0.24-2.59) | 0.74 (0.23-2.41) | 0.67 | 1.04 (0.85-1.28) | ||
| Age at diagnosis ≥50 years | |||||||||
| ER+/PR+ | |||||||||
| Cases/Controls | 139/167 | 155/161 | 169/153 | 156/162 | 176/152 | 795/795 | |||
| RR (95% CI) | ref. | 1.18 (0.84-1.66) | 1.37 (0.97-1.94) | 1.13 (0.80-1.61) | 1.44 (1.00-2.06) | 0.25 | 1.04 (0.97-1.10) | 0.02 | 0.98 |
| ER+ | |||||||||
| Cases/Controls | 285/316 | 309/309 | 290/289 | 270/282 | 294/252 | 1448/1448 | |||
| RR (95% CI) | ref. | 1.14 (0.90-1.45) | 1.17 (0.91-1.51) | 1.06 (0.82-1.37) | 1.34 (1.03-1.75) | 0.14 | 1.03 (0.99-1.08) | 0.05 | 0.97 |
| ER-/PR- | |||||||||
| Cases/Controls | 44/38 | 43/38 | 47/41 | 51/55 | 31/44 | 216/216 | |||
| RR (95% CI) | ref. | 1.13 (0.56-2.28) | 1.06 (0.53-2.10) | 0.78 (0.38-1.57) | 0.47 (0.23-0.98) | 0.03 | 0.87 (0.76-0.98) | 0.43 | |
| ER- | |||||||||
| Cases/Controls | 67/62 | 64/55 | 68/61 | 66/75 | 53/65 | 318/318 | |||
| RR (95% CI) | ref. | 1.22 (0.70-2.13) | 1.03 (0.60-1.78) | 0.74 (0.42-1.29) | 0.65 (0.37-1.15) | 0.10 | 0.92 (0.83-1.02) | 0.50 | |
*
Cutpoints reflect non-log transformed sRANKL/OPG ratio values
†
ptrend based on log2-transformed sRANKL/OPG ratio
‡
pheterogeneity comparing ER+/PR+ to ER-/PR- and ER+ to ER- subtypes, based on RRlog2
§
pheterogeneity comparing age at diagnosis <50 to ≥50 years based on RRlog2; Conditional logistic regression models adjusted for: ages at menarche (<12, 13, 14, ≥15, missing), menopause (<44, 44-47, 48-50, 51-52, 53-54, ≥55, missing), and first full-term pregnancy (no FTP, <25, 25-30, ≥30, missing), and number of full-term pregnancies (0, 1, 2, ≥3, missing) and BMI (kg/m2, continuous).